Serum bone sialoprotein levels and bone metastases

Journal of Cancer Research and Therapeutics

Volumn 7, Issue 2, 2011, Pages 115-119

  Uccello, Mario ^a   Malaguarnera, Giulia ^a   Vacante, Marco ^a   Motta, Massimo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Bone metastasis; bone remodeling; bone sialoprotein; bone turnover markers; breast cancer; multiple myeloma

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; ARGINYLGLYCYLASPARTIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE SIALOPROTEIN; DENTIN MATRIX PROTEIN 1; DENTIN SIALOPHOSPHOPROTEIN; DEOXYPYRIDINOLINE; GELATINASE A; MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; PHOSPHOPROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ALKALINE PHOSPHATASE BLOOD LEVEL; APOPTOSIS; BONE ATROPHY; BONE METABOLISM; BONE METASTASIS; BONE REMODELING; BONE SCINTISCANNING; BONE TURNOVER; BREAST CANCER; CANCER CELL; CELL SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYPERPARATHYROIDISM; IMMUNOHISTOCHEMISTRY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PATIENT MONITORING; PROGNOSIS; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY;

BONE NEOPLASMS; CELL MOVEMENT; HUMANS; INTEGRIN-BINDING SIALOPROTEIN; INTEGRINS; TUMOR MARKERS, BIOLOGICAL;

EID: 79960831854     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.82912     Document Type: Review

References (70)

1. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97:59-69.
2. Terpos E. Biochemical markers of bone metabolism in multiple myeloma. Cancer Treat Rev 2006;32:15-9.
3. Coleman RE. Risks and benefits of bisphosphonates. Br J Cancer 2008;98:1736-40. (Pubitemid 351748847)
4. Lipton A, Berenson JR, Body JJ, Boyce BF, Bruland OS, Carducci MA, et al. Advances in treating metastatic bone cancer: Summary statement for the First Cambridge Conference. Clin Cancer Res 2006;12:6209s-12.
5. Brown JE, Sim S. Evolving role of bone biomarkers in castration-resistant prostate cancer. Neoplasia 2010;12:685-96.
6. Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006;12:6213s-6.
7. Fontana A, Delmas PD. Markers of bone turnover in bone metastases. Cancer 2000; 88: 2952-60. (Pubitemid 30413178)
8. Schoenberger J, Rozeboom S, Wirthgen-Beyer E, Eilles C. Evaluation of the clinical value of bone metabolic parameters for the screening of osseous metastases compared to bone scintigraphy. BMC Nucl Med 2004;4:3.
9. Coleman R, Brown J, Terpos E, Lipton A, Smith MR, Cook R, et al. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev 2008;34:629-39.
10. Shaarawy M, Hasan M. Serum bone sialoprotein: a marker of bone resorption in postmenopausal osteoporosis. Scand J Clin Lab Invest 2001;61:513-21.
11. Fisher LW, Mc Bride OW, Termine JD, Young MF. Human bone sialoprotein. Deduced protein sequence and chromosomal localization. J Biol Chem 1990;265:2347-51.
12. Oldberg A, Franzén A, Heinegård D. The primary structure of a cell-binding bone sialoprotein. J Biol Chem 1988;263:19430-2. (Pubitemid 19016419)
13. Fisher LW, Fedarko NS. Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect Tissue Res 2003;44:33-40. (Pubitemid 36395419)
14. Masi L, Brandi ML, Robey PG, Crescioli C, Calvo JC, Bernabei P, et al. Biosynthesis of bone sialoprotein by a human osteoclast-like cell line (FLG 29.1). J Bone Miner Res 1995;10:187-96.
15. Chen J, Shapiro HS, Sodek J. Development expression of bone sialoprotein m RNA in rat mineralized connective tissues. J Bone Miner Res 1992;7:987-97.
16. Kasugai S, Nagata T, Sodek J. Temporal studies on the tissue compartmentalization of bone sialoprotein (BSP), osteopontin (OPN), and SPARC protein during bone formation in vitro. J Cell Physiol 1992;152:467-77.
17. Sodek J, Overall CM. Matrix metalloproteinases in periodontal tissue remodelling. Matrix Suppl 1992;1:352-62.
18. Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS. Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun 2001;280:460-5. (Pubitemid 32912812)
19. Malaval L, Wade-Guéye NM, Boudiffa M, Fei J, Zirngibl R, Chen F, et al. Bone sialoprotein plays a functional role in bone formation and osteoclastogenesis. J Exp Med 2008;205:1145-53. (Pubitemid 351679689)
20. Valverde P, Tu Q, Chen J. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically. J Bone Miner Res 2005;20:1669-79. (Pubitemid 41243555)
21. Valverde P, Zhang J, Fix A, Zhu J, Ma W, Tu Q, et al. Overexpression of bone sialoprotein leads to an uncoupling of bone formation and bone resorption in mice. J Bone Miner Res 2008;23:1775-88.
22. Ogata Y. Bone sialoprotein and its transcriptional regulatory mechanism. J Periodontal Res 2008;43:127-35.
23. Li Z, Wang Z, Yang L, Li X, Sasaki Y, Wang S, et al. Fibroblast growth factor 2 regulates bone sialoprotein gene transcription in human breast cancer cells. J Oral Sci 2010;52:125-32.
24. Razzouk S, Brunn JC, Qin C, Tye CE, Goldberg HA, Butler WT. Osteopontin posttranslational modifications, possibly phosphorylation, are required for in vitro bone resorption but not osteoclast adhesion. Bone 2002;30:40-7. (Pubitemid 34044299)
25. Hunter GK, Goldberg HA. Modulation of crystal formation by bone phosphoproteins: Role of glutamic acid-rich sequences in the nucleation of hydroxyapatite by bone sialoprotein. Biochem J 1994;302:175-9. (Pubitemid 24256351)
26. Roach HI. Why does bone matrix contain noncollagenous proteins? The possible roles of osteocalcin, osteonectin, osteopontin and bone sialoprotein in bone mineralisation and resorption. Cell Biol Int 1994;18:617-28. (Pubitemid 24239837)
27. Tu Q, Zhang J, Fix A, Brewer E, Li YP, Zhang ZY, et al. Targeted overexpression of BSP in osteoclasts promotes bone metastasis of breast cancer cells. J Cell Physiol 2009;218:135-45.
28. Gordon JA, Tye CE, Sampaio AV, Underhill TM, Hunter GK, Goldberg HA. Bone sialoprotein expression enhances osteoblast differentiation and matrix mineralization in vitro. Bone 2007;41:462-73. (Pubitemid 47199144)
29. Seibel MJ, Woitge HG, Pecherstorfer M, Karmatschek M, Horn E, Ludwig H, et al. Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease. J Clin Endocrinol Metab 1996;81:3289-94. (Pubitemid 26296204)
30. Mansson B, Carey D, Alini M, Ionescu M, Rosenberg LC, Poole AP, et al. Cartilage and bone metabolism in rheumatoid arthritis: Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest 1995;95:1071-7.
31. Saxne T, Zunino L, Heinegard D. Increased release of bone sialoprotein into synovial fluid reflects tissue destruction in rheumatoid arthritis. Arthritis Rheum 1995;38:82-90.
32. Wolfgang W, Armbruster FP, Karmatschek M, Reinauer H. Bone sialoprotein in serum of patients with malignant bone diseases. Clin Chem 1997;43:85-91. (Pubitemid 27024395)
33. Woitge HW, Pecherstorfer M, Horn E, Keck AV, Diel IJ, Bayer P, et al. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. Br J Cancer 2001;84:344-51. (Pubitemid 32154427)
34. Diel IJ, Solomayer EF, Seibel MJ, Pfeilschifter J, Maisenbacher H, Gollan C, et al. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res 1999;5:3914-9. (Pubitemid 30013765)
35. Loibl S, Königs A, Kaufmann M, Costa SD, Bischoff J. PTHr P and bone sialoprotein as prognostic markers for developing bone metastases in breast cancer patients. Zentralbl Gynakol 2006;128:330-5. (Pubitemid 46102229)
36. Chen J, Rodriguez JA, Barnett B, Hashimoto N, Tang J, Yoneda T. Bone sialoprotein promotes tumor cell migration in both in vitro and in vivo models. Connect Tissue Res 2003;44:279-84. (Pubitemid 36395457)
37. Bellahcène A, Merville MP, Castronovo V. Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. Cancer Res 1994;54:2823-6. (Pubitemid 24187753)
38. Bellahcène A, Menard S, Bufalino R, Moreau L, Castronovo V. Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int J Cancer 1996;69:350-3. (Pubitemid 26298303)
39. Gillespie MT, Thomas RJ, Pu ZY, Zhou H, Martin TJ, Findlay DM. Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers. Int J Cancer 1997;73:812-5. (Pubitemid 127483032)
40. Ibrahim T, Leong I, Sanchez-Sweatman O, Khokha R, Sodek J, Tenenbaum HC, et al. Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. Clin Exp Metastasis 2000;18: 253-60. (Pubitemid 32269995)
41. Papotti M, Kalebic T, Volante M, Chiusa L, Bacillo E, Cappia S, et al. Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: A retrospective case-control study. J Clin Oncol 2006;24:4818-24. (Pubitemid 46630907)
42. Zhang L, Hou X, Lu S, Rao H, Hou J, Luo R, et al. Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: A large cohort retrospective study. Lung Cancer 2010;67:114-9.
43. Waltregny D, Bellahcène A, Van Riet I, Fisher LW, Young M, Fernandez P, et al. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Natl Cancer Inst 1998;90:1000-8. (Pubitemid 28340442)
44. Bellahcène A, Albert V, Pollina L, Basolo F, Fisher LW, Castronovo V. Ectopic expression of bone sialoprotein in human thyroid cancer. Thyroid 1998;8:637-41. (Pubitemid 28405148)
45. Bellahcène A, Kroll M, Liebens F, Castronovo V. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. J Bone Miner Res 1996;11:665-70. (Pubitemid 26123917)
46. Waltregny D, Bellahcène A, de Leval X, Florkin B, Weidle U, Castronovo V. Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers. J Bone Miner Res 2000;15:834-43. (Pubitemid 30233406)
47. Sung V, Stubbs JT 3rd, Fisher L, Aaron AD, Thompson EW. Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the alpha(v)beta3 and alpha(v)beta5 integrins. J Cell Physiol 1998;176:482-94. (Pubitemid 28383909)
48. Ross FP, Chappel J, Alvarez JI, Sander D, Butler WT, Farach-Carson MC, et al. Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. J Biol Chem 1993;268:9901-7. (Pubitemid 23146055)
49. Byzova TV, Kim W, Midura RJ, Plow EF. Activation of integrin alpha(V) beta(3) regulates cell adhesion and migration to bone sialoprotein. Exp Cell Res 2000;254:299-308. (Pubitemid 30080586)
50. Karadag A, Oqbureke KU, Fedarko NS, Fisher LW. Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion. J Natl Cancer Inst 2004;96:956-65. (Pubitemid 38868142)
51. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996;12:697-715. (Pubitemid 26422728)
52. Karadag A, Fisher LW. Bone sialoprotein enhances migration of bone marrow stromal cells through matrices by bridging MMP-2 to alpha(v) beta3-integrin. J Bone Miner Res 2006;21:1627-36. (Pubitemid 44484608)
53. Nam JS, Suchar AM, Kang MJ, Stuelten CH, Tang B, Michalowska AM, et al. Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. Cancer Res 2006;66:6327-35.
54. Pardali K, Moustakas A. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 2007;1775:21-62. (Pubitemid 44881193)
55. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74. (Pubitemid 37328786)
56. Overall CM, Kleifeld O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer 2006;94:941-6.
57. Hwang Q, Cheifetz S, Overall CM, Mc Culloch CA, Sodek J. Bone sialoprotein does not interact with pro-gelatinase A (MMP-2) or mediate MMP-2 activation. BMC Cancer 2009;9:121.
58. Zhang JH, Tang J, Wang J, Ma W, Zheng W, Yoneda T, et al. Over-expression of bone sialoprotein enhances bone metastasis of human breast cancer cells in a mouse model. Int J Oncol 2003;23:1043-8.
59. Zhang JH, Wang J, Tang J, Barnett B, Dickson J, Hahsimoto N, et al. Bone sialoprotein promotes bone metastasis of a non-bone-seeking clone of human breast cancer cells. Anticancer Res 2004;24:1361-8. (Pubitemid 38954650)
60. Bellahcène A, Bonjean K, Fohr B, Fedarko NS, Robey FA, Young MF, et al. Bone sialoprotein mediates human endothelial cell attachment and migration and promotes angiogenesis. Circ Res 2000;86:885-91. (Pubitemid 30246986)
61. Adwan H, Bäuerle T, Najajreh Y, Elazer V, Golomb G, Berger MR. Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells. Int J Oncol 2004;24:1235-44.
62. Bäuerle T, Adwan H, Kiessling F, Hilbig H, Armbruster FP, Berger MR. Characterization of a rat model with site-specific bone metastasis induced by MDA-MB-231 breast cancer cells and its application to the effects of an antibody against bone sialoprotein. Int J Cancer 2005;115:177-86. (Pubitemid 40586725)
63. Melquist JJ, Kacka M, Li Y, Malaeb BS, Elmore J, Baseman AG, et al. Conditionally replicating adenovirus-mediated gene therapy in bladder cancer: an orthotopic in vivo model. Urol Oncol 2006;24: 362-71. (Pubitemid 43963413)
64. Jung K, Lein M, Stephan C, Von Hösslin K, Semjonow A, Sinha P, et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: Diagnostic and prognostic implications. Int J Cancer 2004;111:783-91. (Pubitemid 39062904)
65. Fedarko NS, Fohr B, Robey PG, Young MF, Fisher LW. Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack. J Biol Chem 2000;275:16666-72. (Pubitemid 30398895)
66. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001;7:4060-6. (Pubitemid 34044628)
67. Jain A, Mc Knight DA, Fisher LW, Humphreys EB, Mangold LA, Partin AW, et al. Small integrin-binding proteins as serum markers for prostate cancer detection. Clin Cancer Res 2009;15:5199-207.
68. Schindler F, Lajolo PP, Pinczowski H, Fonseca FL, Barbieri A, Massonetto LH, et al. Bone and total alkaline phosphatase for screening skeletal metastasis in patients with solid tumours. Eur J Cancer Care (Engl) 2008;17:152-6.
69. Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008;113:193-201. (Pubitemid 351976401)
70. Lipton A, Costa L, Ali SM, Demers LM. Bone markers in the management of metastatic bone disease. Cancer Treat Rev 2001;27:181-5. (Pubitemid 32452019)